This single‐center, retrospective cohort study included patients with advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, HER2 alterations or driver‐negative, and were treated with first‐line ICI therapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.